Merck KGaA Says New Meds Will Add €2bn Sales

The German group believes its €2bn target of pipeline sales by 2022 is achievable. It is hoping for a healthy contribution from rare lung cancer drug tepotinib.

Euro_Notes_500
Merck hopeful of €2bn from pipeline sales by 2022 • Source: Shutterstock

More from Clinical Trials

More from R&D